Tower Research Capital (TRC)’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-262
| Closed | -$1.94K | – | 5481 |
|
|
2026
Q1 | $1.94K | Sell |
262
-302
| -54% | -$1.97K | ﹤0.01% | 4574 |
|
|
2025
Q4 | $3.55K | Sell |
564
-623
| -52% | -$3.63K | ﹤0.01% | 4353 |
|
|
2025
Q3 | $4.63K | Buy |
1,187
+1,042
| +719% | +$4.27K | ﹤0.01% | 4317 |
|
|
2025
Q2 | $664 | Buy |
+145
| New | +$622 | ﹤0.01% | 4968 |
|
|
2025
Q1 | – | Sell |
-1,036
| Closed | -$6.96K | – | 5528 |
|
|
2024
Q4 | $6.96K | Buy |
1,036
+47
| +5% | +$350 | ﹤0.01% | 4119 |
|
|
2024
Q3 | $7.64K | Sell |
989
-1,317
| -57% | -$7.94K | ﹤0.01% | 4033 |
|
|
2024
Q2 | $13.8K | Buy |
2,306
+1,653
| +253% | +$12.6K | ﹤0.01% | 3972 |
|
|
2024
Q1 | $5.89K | Sell |
653
-495
| -43% | -$4.51K | ﹤0.01% | 4471 |
|
|
2023
Q4 | $10.9K | Buy |
1,148
+101
| +10% | +$888 | ﹤0.01% | 4190 |
|
|
2023
Q3 | $12.5K | Sell |
1,047
-1,651
| -61% | -$29.3K | ﹤0.01% | 3889 |
|
|
2023
Q2 | $66.1K | Buy |
2,698
+827
| +44% | +$21.5K | ﹤0.01% | 2351 |
|
|
2023
Q1 | $59K | Buy |
1,871
+1,758
| +1,556% | +$102K | ﹤0.01% | 2351 |
|
|
2022
Q4 | $8K | Sell |
113
-565
| -83% | -$41.9K | ﹤0.01% | 4414 |
|
|
2022
Q3 | $58K | Buy |
678
+319
| +89% | +$31K | ﹤0.01% | 3023 |
|
|
2022
Q2 | $30K | Sell |
359
-302
| -46% | -$26.6K | ﹤0.01% | 3381 |
|
|
2022
Q1 | $110K | Buy |
661
+190
| +40% | +$27.3K | ﹤0.01% | 2133 |
|
|
2021
Q4 | $79K | Buy |
471
+120
| +34% | +$13.5K | ﹤0.01% | 2392 |
|
|
2021
Q3 | $31K | Sell |
351
-111
| -24% | -$7.35K | ﹤0.01% | 3354 |
|
|
2021
Q2 | $25K | Buy |
462
+222
| +93% | +$12.6K | ﹤0.01% | 3678 |
|
|
2021
Q1 | $14K | Sell |
240
-1,425
| -86% | -$83.3K | ﹤0.01% | 4151 |
|
|
2020
Q4 | $86K | Sell |
1,665
-1,415
| -46% | -$78.7K | ﹤0.01% | 2498 |
|
|
2020
Q3 | $149K | Buy |
3,080
+2,459
| +396% | +$118K | ﹤0.01% | 2821 |
|
|
2020
Q2 | $32K | Buy |
+621
| New | +$31.3K | ﹤0.01% | 3401 |
|
|
2019
Q4 | – | Sell |
-127
| Closed | -$4K | – | 3981 |
|
|
2019
Q3 | $4K | Buy |
127
+123
| +3,075% | +$5.94K | ﹤0.01% | 3425 |
|
|
2019
Q2 | $0 | Sell |
4
-172
| -98% | -$26.7K | ﹤0.01% | 3993 |
|
|
2019
Q1 | $31K | Buy |
176
+166
| +1,660% | +$32.7K | ﹤0.01% | 2018 |
|
|
2018
Q4 | $2K | Buy |
+10
| New | +$2.44K | ﹤0.01% | 3381 |
|
Tower Research Capital (TRC)'s KZR Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 262 shares — an estimated $1.94K sold.
Tower Research Capital (TRC) first reported a position in KZR in Q4 2018 and held it in 27 quarters. The position peaked at $149K in Q3 2020. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 262 Kezar Life Sciences shares in Q2 2026, an estimated $1.94K.
- Tower Research Capital (TRC) first reported a position in Kezar Life Sciences in Q4 2018 and held it in 27 quarters.
- Tower Research Capital (TRC)'s Kezar Life Sciences position peaked at $149K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.